$11.66 2.7%
SPRY Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions.

ARS Pharmaceuticals
Price $11.66
Target Price Sign up
Volume 696,340
Market Cap $1.1B
Year Range $3.43 - $11.66
Dividend Yield 0%
Revenue per Employee $500
Industry Biotechnology

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24093,000-93,000-10M-13M-0.110
Q4 '230-40M40M-7.2M-10M-0.070
Q3 '23015M-15M-15M-18M-0.160
Q2 '2310,00013M-13M-17M-21M-0.180
Q1 '2320,00012M-12M-15M-19M-0.160

Insider Transactions View All

Lowenthal Richard E filed to sell 1,648,499 shares at $9.6.
July 11 '24
Tanimoto Sarina filed to sell 1,648,499 shares at $9.6.
July 11 '24
Lowenthal Richard E filed to sell 1,546,494 shares at $9.1.
June 13 '24
Lowenthal Richard E filed to sell 1,698,499 shares at $9.1.
June 13 '24
Tanimoto Sarina filed to sell 1,546,494 shares at $9.1.
June 13 '24

What is the Market Cap of ARS Pharmaceuticals?

The Market Cap of ARS Pharmaceuticals is $1.1B.

How Many People Work at ARS Pharmaceuticals?

As of our latest update, ARS Pharmaceuticals employed approximately 20 people worldwide. However, it's important to note that ARS Pharmaceuticals' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is ARS Pharmaceuticals' revenue per employee?

$500. To calculate ARS Pharmaceuticals' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of ARS Pharmaceuticals?

Currently, the price of one share of ARS Pharmaceuticals stock is $11.66.

How can I analyze the SPRY stock price chart for investment decisions?

The SPRY stock price chart above provides a comprehensive visual representation of ARS Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ARS Pharmaceuticals shares. Our platform offers an up-to-date SPRY stock price chart, along with technical data analysis and alternative data insights.

Does SPRY offer dividends to its shareholders?

As of our latest update, ARS Pharmaceuticals (SPRY) does not offer dividends to its shareholders. Investors interested in ARS Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of ARS Pharmaceuticals?

Some of the similar stocks of ARS Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.